GlaxoSmithKline Appoints Andrew Witty CEO Designate
LONDON, Oct. 8, 2007-The Board of GlaxoSmithKline plc (“GSK”) (LSE & NYSE: GSK) today announced the appointment of Andrew Witty as CEO Designate, GlaxoSmithKline.
Andrew Witty, currently President, Pharmaceuticals Europe for GlaxoSmithKline, will succeed Dr Jean-Pierre Garnier following his retirement as Chief Executive Officer at the end of May 2008.
Sir Christopher Gent, Chairman, GlaxoSmithKline said: “Andrew’s appointment follows a rigorous selection process by the Board of Directors. The fact that we have been able to select a successor to JP from three strong internal candidates is a testament to the quality of management at GSK. The Board is confident that Andrew will build on JP’s considerable achievements which have positioned GSK as a leader of the pharmaceutical industry.”
JP Garnier said: “Andrew has made many significant
contributions to GSK and I am very pleased that he is to be our
next CEO. I look forward to working with him during our handover
and wish him every success.”
GlaxoSmithKline — one of the world’s leading
research-based pharmaceutical and healthcare companies — is
committed to improving the quality of human life by enabling people
to do more, feel better and live longer.
Enquiries:
UK Media enquiries:
Philip Thomson
(020) 8047 5502
Alice Hunt
(020) 8047 5502
Joss Mathieson
(020) 8047 5502
Claire Brough
(020) 8047 5502
US Media enquiries:
Nancy Pekarek
(215) 751 7709
Mary Anne Rhyne
(919) 483 2839
European Analyst/Investor enquiries:
David Mawdsley
(020) 8047 5564
Sally Ferguson
(020) 8047 5543
US Analyst/ Investor enquiries:
Frank Murdolo
(215) 751 7002
Tom Curry
(215) 751 5419
Notes to Editors:
Andrew Witty was appointed President, Pharmaceuticals Europe for
GlaxoSmithKline in January 2003. He is a member of the Corporate
Executive Team. Previously, he held the role of Senior Vice
President, Asia Pacific, based in Singapore.
Andrew joined Glaxo UK in 1985. He held various positions in the UK, including Director of Pharmacy and Distribution, International Product Manager and a variety of other sales & marketing positions. He later served as Managing Director, Glaxo South Africa and Area Director for South and East Africa. Immediately prior to his move to Asia Pacific, he was Vice President and General Manager, Marketing for Glaxo Wellcome Inc, the company's US subsidiary, where he had responsibility for strategy development, marketing execution and new product positioning.
While in Singapore Andrew served as Economic Advisor to the Governor of Guangzhou, China from 2000 to 2002. He was also a member of the Singapore Economic Development Board, and sat on the Economic Development Board audit committee and the Singapore Land Authority Board.
Andrew is a member of the INSEAD UK Council, a member of the
interim board of OSCHR (the Office for Strategic Coordination of
Health Research), sits on the Imperial College Commercialisation
Advisory Board and is a member of the London Council for the
Advancement of Science and Technology. He is a member of the Pharma
Futures Working Group, and of the UK’s newly created Health
Innovation Council.
Andrew is 43 years old and is married with 2 children. He enjoys
tennis, running and watching rugby and cricket. He has a BA in
economics from Nottingham University in the UK.
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
